Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 12, 2017 - Issue
Submit an article Journal homepage
79
Views
34
CrossRef citations to date
0
Altmetric
Original Research

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD

Antonio R Anzueto1 University of Texas Health Science Center;2 South Texas Veterans Healthcare System, University of Texas, San Antonio, TX, United States
,
Claus F Vogelmeier3 Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Marburg, Germany
,
Konstantinos Kostikas4 Novartis Pharma AG, Basel, Switzerland
,
Karen Mezzi4 Novartis Pharma AG, Basel, Switzerland
,
Sebastian Fucile5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
,
Giovanni Bader4 Novartis Pharma AG, Basel, Switzerland
,
Steven Shen5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
,
Donald Banerji5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
&
Robert Fogel5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesCorrespondence[email protected]
 show all
Pages 1325-1337 | Published online: 04 May 2017

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.